Micro-focal prostate cancer: A comparison of biopsy and radical prostatectomy specimen features

European Urology

Volumn 48, Issue 6, 2005, Pages 895-899

  Boccon Gibod, L M ^a   Dumonceau, O ^a   Toublanc, M ^a   Ravery, V ^a   Boccon Gibod, L A ^b  

^a BICHAT HOSPITAL   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Micro focal; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER GRADING; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; TISSUE SECTION; TRANSRECTAL ULTRASONOGRAPHY; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; BIOPSY, NEEDLE; FOLLOW-UP STUDIES; FROZEN SECTIONS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 27844606067     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.04.033     Document Type: Review

References (25)

1. M.R. Cooperberg, J.M. Broering, M.S. Litwin, D.P. Lubeck, S.S. Mehta, J.M. Henning and the CaPsure investigators The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CaPsure) a national disease registry J Urol 171 2004 1393 1401
2. R.F. Hoedemaeker, J.B.W. Rietbergen, R. Kranse, F.H. Schroder, and T.H. van der Kwast Histopathological prostate cancer characteristics at radical prostatectomy after population based screening J Urol 164 2000 411 415
3. C. Parker Active surveillance: towards a new paradigm in the management of early prostate cancer Lancet Oncol 5 2004 101 106
4. Khan MA, Partin AW, Carter HB. Expectant management of localized prostate cancer. Urology 2003;62:793-799.
5. L. Klotz Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer Eur Urol 47 2005 16 21
6. V. Ravery, J. Szabo, M. Toublanc, LA. Boccon Gibod, T. Billebaud, and J.F. Hermieu A single positive biopsy in six does not predict a low volume prostate tumour Br J Urol 77 5 1996 724 728
7. A.K. Lee, T. Doytchinova, M.H. Chen, A.A. Renshax, M. Weinstein, and J.P. Riou Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed the basis of a single positive core? Urol Oncol 21 2003 123 127
8. J.W. Anast, G.L. Andriole, T.A. Bismar, Y. Yan, and P.A. Humphrey Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 64 2004 544 550
9. M. Noguchi, T.A. Stamey, J.E. McNeal, and R. Nolley Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers J Urol 170 2003 459 463
10. J. Esptein Pathological assessment of the surgical specimens Urol Clin N Am 28 2001 567 594
11. G. Draisma, R. Boer, S.J. Otto, I.W. Can Der Cruijsen, R.A.M. Damhuis, and F.H. Scroder Lead times and overdection due to prostate-specific antigen screening: estimates from the european randomized study of screening for prostate cancer J Nat Cancer Inst. 95 2003 868 878
12. U.L. Brendler Pathological and clinical findings to predict tumor extent of non palpable (T1C) prostate cancer Jama 271 1994 368 374
13. T.A. Gardner, M.L. Lemer, P.N. Schlegel, R.S. Waldbaum, E.D. Vaughan, and J. Steckel Microfocal prostate cancer: biopsy cancer volume does not predict actual tumour volume Brit J Urol 81 1998 839 843
14. M.K. Terris, J.F. McNeal, and T.A. Stamey Detection of clinically significant prostate cancer by transrectal ultrasound guided biopsies J Urol 148 1992 829 832
15. Y. Allory, Z. Merabet, L. Salomon, S. Swiebs, D. Vordos, and A. Hoznek Risque de cancer non significatif chez les patients ayant eu un protocole de biopsies en saturation, traités par la prostatectomie radicale Prog Urol 14 supl 1 2004 abstract 06
16. R.F. Hoedemaeker, T.H. van der Kwast, and F.H. Schroder The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy BJU international 92 2 2003 92 96
17. A.M. Truskinovsky, H. Sanderson, and J.I. Epstein Characterization of minute adenocarcinomas of prostate at radical prostatectomy Urology 64 2004 733 737
18. K. Herkommer, R. Kuefer, J.E. Gshwend, R.E. Hautmann, and B.G. Volkmer Pathological to prostate cancer without neoadjuvant therapy: clinical presentation and follow up Eur Urol 45 2004 36 41
19. D.G. Bostwick, and K.C. Bostwick "Vanishing" prostate cancer in radical prostatectomy specimen incidence and long-term follow up in 38 cases BJU Int 94 1 2004 57 58
20. D. Klifa, L. Salomon, Y. Allory, A. de la Taille, D. Vordos, and R. Yiou PT0 après prostatectomie radicale, présentation clinique et pronostique Prog Urol 14 suppl 1 2004 abstract 0152
21. Allan RW, Sanderson H, Epstein JI. Correlation of minute (0.5 mm of less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2003;170:370-2.
22. M.W. Kattan, J.E. Estham, T.M. Wheeler, N. Maru, P.T. Scardino, and A. Erbersdobler Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors J Urol 170 2003 1792 1797
23. P.J. Bastian, L.A. Mangolb, J.I. Epstein, and A.W. Partin Characteristics of insignificant clinical T1 C prostate tumors, a contemporary analysis Cancer 101 2004 2001 2005
24. E.A. Klein What is "insignificant" prostate carcinoma? Cancer 101 2004 1923 1925
25. P.R. Caroll Early stage prostate cancer: do we have problem with over detection, overtreatment or both? J Urol 173 2005 1061 1062